OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: NSC-Therapeutics GmbH

1 Projects | 1 Researchers | $4,998,336 Invested

2024

NSC-Therapeutics GmbH

Manfred Windisch, PhD

A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease

  • Funding Amount: $4,998,336
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active